RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug targets Hard-to-Treat lymphoma
Disease control OngoingThis early-stage trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have come back or not responded to treatment. The main goals are to find the best dose and check for side effects. The drug works by helping the immune system attack cance…
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo therapy offers hope for patients with relapsed T-Cell lymphoma
Disease control OngoingThis study tests a combination of two drugs, pembrolizumab (an immunotherapy that helps the immune system attack cancer) and romidepsin (a drug that blocks enzymes cancer cells need to grow), in people with peripheral T-cell lymphoma that has come back or stopped responding to tr…
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug duo takes on tough lymphomas
Disease control OngoingThis early-stage trial is testing a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and to see if the combination can shrink tumors. About 48…
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:19 UTC